Global IgA Nephropathy Treatment Market Report and Forecast 2023-2031

Global IgA Nephropathy Treatment Market Report and Forecast 2023-2031

Global IgA Nephropathy Treatment Market Outlook

The global IgA nephropathy treatment market size was valued at USD 245.8 million in 2022 and is projected to grow at a CAGR of 4.2% during the forecast period of 2023-2031 to reach a value of USD 356.0 million by 2031. The market growth can be attributed to the increasing prevalence of IgA nephropathy, growing awareness about kidney diseases, and advancements in treatment options.

Global IgA Nephropathy Treatment Market: Introduction

IgA nephropathy, also known as Berger's disease, is a kidney disorder caused by the deposition of the immunoglobulin A (IgA) antibody in the kidneys, leading to inflammation and potential kidney damage. The treatment options for IgA nephropathy include medication, dietary changes, and supportive care. The increasing prevalence of IgA nephropathy, coupled with the rising awareness about kidney diseases, is driving the demand for effective treatment options.

Advancements in medical research have led to the development of new treatment options for IgA nephropathy, including targeted therapies and novel immunosuppressive drugs. Additionally, the growing awareness about kidney diseases and the need for early diagnosis and treatment are also expected to drive market growth.

IgA Nephropathy Epidemiology

According to the National Kidney Foundation, IgA nephropathy is the most common primary glomerulonephritis worldwide, affecting an estimated 2.5 million people globally. The prevalence of IgA nephropathy varies among countries, with higher rates observed in Asia, particularly in Japan and China. The disease affects both men and women, with a higher prevalence in males.

Efforts to improve access to IgA nephropathy treatment should take into account the unique needs of different regions, as well as the underlying factors that contribute to the development of the disease, such as genetics, environmental factors, and lifestyle choices. By addressing these factors, we can work towards reducing the burden of IgA nephropathy and improving access to effective treatment.

IgA Nephropathy Treatment Market Segmentations

The market can be segmented based on diagnosis methods, treatment methods, diseases type, symptoms, age group, route of administration, treatment channel, distribution channel, end-user, and region:

Market Breakup by Diagnosis Method

  • Blood Test
  • Urine Test
  • Kidney Biopsy
  • Iothalamate Clearance Test
  • Others
Market Breakup by Treatment Method
  • Corticosteroid Drugs
  • Immunosuppressive Drugs
  • ACE inhibitors and ARBs
  • Others
Market Breakup by Disease Type
  • Primary IgA Nephropathy
  • Secondary IgA Nephropathy
Market Breakup by Symptoms
  • Haematuria
  • Proteinuria
  • Oedema
  • Others
Market Breakup by Age Group
  • Adults
  • Children
Market Breakup by Route of Administration
  • Oral
  • Tablets/Pills
  • Capsules
  • Others
  • Parenteral
  • Intravenous
  • Intramuscular
  • Others
  • Others
IgA Nephropathy Treatment Market Breakup by Treatment Channel
  • Public
  • Private
Market Breakup by Distribution Channel of Drugs
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Direct Tender
  • Others
Market Breakup by End User
  • Hospitals
  • Clinics
  • Home Healthcare
  • Others
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
IgA Nephropathy Treatment Market Analysis

The market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of IgA nephropathy, rising awareness about kidney diseases, and advancements in treatment options.

North America is currently the largest market for IgA nephropathy treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of IgA nephropathy, a well-established healthcare infrastructure, and strong investment in medical research and development. In addition, the growing adoption of new treatment options and increased awareness about kidney diseases are further driving the growth of the market in North America.

Europe is also a significant market for IgA nephropathy treatment, with countries such as the UK, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of kidney diseases, and government initiatives to address kidney health concerns. Additionally, the region has a well-established healthcare system, which supports the delivery of IgA nephropathy treatment. Asia Pacific is another region that is experiencing significant growth in the IgA nephropathy treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of kidney diseases, and the growing adoption of new treatment options. In addition, government initiatives to address kidney health concerns are helping to drive the growth of the market in the region.

Key Players in the Global IgA Nephropathy Treatment Market

The report provides a detailed analysis of the key players involved in the IgA nephropathy treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
  • Novartis AG
  • Calliditas Therapeutics AB
  • Chinook Therapeutics Inc.
  • Travere Therapeutics Inc.
  • Omeros Corporation
  • VIFOR Pharma
  • Vera Therapeutics Inc.
  • Merck KGaA
  • Reata Pharmaceuticals Inc.
  • Ionis Pharmaceuticals Inc.
  • Apellis Pharmaceuticals Inc.
  • Otsuka Pharmaceutical Co. Ltd


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 IgA Nephropathy Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Rate
7.3 Awareness and Prevention Gaps
8 Global IgA Nephropathy Treatment Market
8.1 Global IgA Nephropathy Treatment Market Overview
8.2 Global IgA Nephropathy Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global IgA Nephropathy Treatment Market Historical Value (2016-2022)
8.2.1.2 Global IgA Nephropathy Treatment Market Forecast Value (2023-2031)
8.3 Global IgA Nephropathy Treatment Market by Diagnosis Method
8.3.1 Market Overview
8.3.1.1 Blood Test
8.3.1.2 Urine Test
8.3.1.3 Kidney Biopsy
8.3.1.4 Iothalamate Clearance Test
8.3.1.5 Others
8.4 Global IgA Nephropathy Treatment Market by Treatment Method
8.4.1 Market Overview
8.4.1.1 Corticosteroid Drugs
8.4.1.2 Immunosuppressive Drugs
8.4.1.3 ACE inhibitors and ARBs
8.4.1.4 Others
8.5 Global IgA Nephropathy Treatment Market by Disease Type
8.5.1 Market Overview
8.5.1.1 Primary IgA Nephropathy
8.5.1.2 Secondary IgA Nephropathy
8.6 Global IgA Nephropathy Treatment Market by Symptoms
8.6.1 Market Overview
8.6.1.1 Hematuria
8.6.1.2 Proteinuria
8.6.1.3 Edema
8.6.1.4 Others
8.7 Global IgA Nephropathy Treatment Market by Age Group
8.7.1 Market Overview
8.7.1.1 Adults
8.7.1.2 Children
8.8 Global IgA Nephropathy Treatment Market by Route of Administration
8.8.1 Market Overview
8.8.1.1 Oral
8.8.1.1.1 Tablets/Pills
8.8.1.1.2 Capsules
8.8.1.1.3 Others
8.8.1.2 Parenteral
8.8.1.2.1 Intravenous
8.8.1.2.2 Intramuscular
8.8.1.2.3 Others
8.8.1.3 Others
8.9 Global IgA Nephropathy Treatment Market by Treatment Channel
8.9.1 Public
8.9.2 Private
8.10 Global IgA Nephropathy Treatment Market by Distribution Channel
8.10.1 Market Overview
8.10.1.1 Hospital Pharmacy
8.10.1.2 Retail Pharmacy
8.10.1.3 Online Pharmacy
8.10.1.4 Direct Tender
8.10.1.5 Others
8.11 Global IgA Nephropathy Treatment Market by End User
8.11.1 Market Overview
8.11.1.1 Hospitals
8.11.1.2 Clinics
8.11.1.3 Home Healthcare
8.11.1.4 Others
8.12 Global IgA Nephropathy Treatment Market by Region
8.12.1 Market Overview
8.12.1.1 North America
8.12.1.2 Europe
8.12.1.3 Asia Pacific
8.12.1.4 Latin America
8.12.1.5 Middle East and Africa
9 North America IgA Nephropathy Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe IgA Nephropathy Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific IgA Nephropathy Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America IgA Nephropathy Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa IgA Nephropathy Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global IgA Nephropathy Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Novartis AG
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Calliditas Therapeutics AB
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Chinook Therapeutics Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Travere Therapeutics Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Omeros Corporation
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 VIFOR Pharma
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Vera Therapeutics Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Merck KGaA
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Reata Pharmaceuticals Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Ionis Pharmaceuticals Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Apellis Pharmaceuticals Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Otsuka Pharmaceutical Co. Ltd
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
16 Global IgA Nephropathy Treatment Market - Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings